Research, kept separate from care
Understand how scientific ideas are examined before they can inform clinical care.
A promising laboratory result leaves practical questions unanswered: whether an approach is relevant to people, what the uncertainties are, how it can be evaluated and who is accountable. Clinical translation is the disciplined work of answering those questions.
Before an approach can inform care, it is reviewed for its scientific rationale, quality of evidence, safety, regulatory requirements and practical delivery. Research also needs an appropriate protocol, independent oversight and meaningful measurements. An approach may need more evidence or may not proceed to clinical use.
HLC’s relationship with LongevityTech.fund connects the clinic with researchers and companies developing new approaches to healthy aging. Research & Frontier explains how emerging science is evaluated, what needs to be measured and how findings can inform future clinical work. Scientific or investment relationships do not establish that a treatment works or is appropriate for you. Clinical recommendations and research eligibility remain independent.
Researchers and technology teams can request a separate scientific conversation. This route is for evaluating collaboration, not for clients seeking access to an intervention. People seeking care should use the clinical consultation route.
Healthy Longevity Clinic's program reached the Top 40 of XPRIZE Healthspan. In a small proof-of-concept study, statistically significant pre/post changes were detectable within eight weeks.
Healthy Longevity Clinic was a 2025 XPRIZE Healthspan Milestone 1 award recipient. The program evaluated in the competition combined a measured starting point, coordinated care and repeat measurement. Each client’s plan is adapted to their health, priorities and clinical assessment.
Several measures showed statistically significant pre/post improvement during the eight-week program, including a DNA-methylation pace-of-aging measure, HbA1c and Timed Up and Go. The short study window is practically encouraging: progress was measurable in weeks, supporting earlier reassessment during care. This was a single-arm study with 10 participants and no randomized control group. It cannot prove that the program caused every change or predict how quickly an individual client will improve.
The source report describes a prospective, single-arm, open-label, within-participant pre/post feasibility evaluation. Ten participants completed an eight-week multimodal programme. Mean age at baseline was 78.1 years (range 71–84); seven participants were women and three were men. There was no randomized control group.
The report used paired pre/post analysis for each endpoint, 95% confidence intervals, paired effect sizes and exact sign-flip permutation tests. The number of paired observations varied from seven to ten for some measures. The primary table reports unadjusted p-values across many endpoints, so individual findings need cautious interpretation.
Researchers and technology teams can contact HLC about scientific evaluation and collaboration. If you are seeking personal care, use the separate clinical consultation route.
